Business Wire

Samsung Bioepis Announces Phase 3 Results of SB8, Bevacizumab Biosimilar Candidate, at the European Society for Medical Oncology (ESMO) 2019 Congress

Share

Samsung Bioepis Co., Ltd. today announced results from the Phase 3 study evaluating the efficacy and safety of SB8, a bevacizumab biosimilar candidate, compared to reference bevacizumab in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC).ii The study results will be presented for the first time today at the European Society for Medical Oncology (ESMO) 2019 Congress in Barcelona, Spain.

“Data from this study showed that there were no clinically meaningful differences between SB8 and reference bevacizumab in terms of efficacy, safety, pharmacokinetics and immunogenicity,” said Chul Kim, Senior Vice President and Head of Clinical Sciences Division, Samsung Bioepis. “We are committed to increasing access to high-quality, life-changing oncology medicines through the development of biosimilars to address some of oncology’s most pressing challenges.”

The primary endpoint of the study was the overall response rate (ORR) by 24 weeks; risk ratio was analyzed in the full analysis set (FAS) with pre-defined equivalence margin of 0.737 to 1.357 and the risk difference was analyzed in the per-protocol set (PPS) with pre-defined equivalence margin of ±12.5%. The ORR in FAS was 47.6% for SB8 and 42.8% for reference bevacizumab; the risk ratio was 1.11 (90% CI: 0.975, 1.269). The ORR in PPS was 50.1% for SB8 and 44.8% for reference bevacizumab; the risk difference was 5.3% (95% CI: −2.2%, 12.9%). The median progression-free survival (8.5 months vs 7.9 months) and overall survival (14.9 months vs. 15.8 months) were comparable between SB8 and reference bevacizumab. The overall incidence of treatment-emergent adverse events (92.1% vs 91.1%) and the incidence of overall anti-drug antibodies (16.1% vs 11.0%) were also comparable between SB8 and reference bevacizumab.

Marketing Authorization Application (MAA) for SB8 was accepted for review by the European Medicines Agency (EMA) in July 2019.

The results of the SB8 Phase 3 study will be presented as a poster during ESMO as follows: [1565P] 12:00-13:00, September 28, Hall 4. Samsung Bioepis will also host a satellite symposium, titled ‘Quality Assurance to Optimize HER2+ Breast Cancer Treatment’, which will discuss the importance of quality maintenance in oncology biologics. The symposium will take place between 13:00-14:30 on September 30, 2019 in Toledo Auditorium, Hall 5, Fira Gran Via, Barcelona. Topics include:

  • Building confidence in biosimilars
  • Acknowledging importance of biologics quality in clinical practice
  • Reassuring biosimilarity based on clinical evidence
  • Interactive discussion: perspective on biosimilars in oncology

SB8 Phase 3 Study

The SB8 Phase 3 study is a randomized, double-blind, multicenter study evaluating the efficacy, safety, pharmacokinetics (PK), and immunogenicity of SB8 compared to reference bevacizumab in combination with paclitaxel and carboplatin in patients with metastatic or recurrent non-squamous non-small cell lung cancer (NSCLC). 763 patients were randomized (1:1) to receive SB8 or reference bevacizumab with paclitaxel and carboplatin Q3W followed by SB8 or reference bevacizumab maintenance therapy until disease progression, unacceptable toxicity, death, or 1 year from the randomization of the last patient. The primary endpoint is the overall response rate (ORR) which is defined as the proportion of patients whose best overall response by 24 weeks is either complete response or partial response. Secondary endpoints were progression free survival (PFS), overall survival (OS), duration of response (DOR), safety, PK, and immunogenicity.

About Samsung Bioepis Co., Ltd.

Established in 2012, Samsung Bioepis is a biopharmaceutical company committed to realizing healthcare that is accessible to everyone. Through innovations in product development and a firm commitment to quality, Samsung Bioepis aims to become the world's leading biopharmaceutical company. Samsung Bioepis continues to advance a broad pipeline of biosimilar candidates that cover a spectrum of therapeutic areas, including immunology, oncology, ophthalmology and hematology. Samsung Bioepis is a joint venture between Samsung BioLogics and Biogen. For more information, please visit: www.samsungbioepis.com.

_____________________________

i AVASTIN is a registered trademark of Genentech Inc.

ii Reck et al. A Phase III Study comparing SB8, a Proposed Bevacizumab Biosimilar, and Reference Bevacizumab in Patients with Metastatic or Recurrent Non-squamous NSCLC. ESMO 2019, Barcelona, Spain [1565P]

Contact information

Na Yun KIM
+82-31-8061-1604
nayun86.kim@samsung.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

STELARA® (ustekinumab) Data Demonstrate Long-term Efficacy and Safety Results in Adults With Moderately to Severely Active Ulcerative Colitis in Phase 3 Extension Trial21.10.2019 12:12:00 CESTPress release

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new two-year data from the long-term extension of the Phase 3 UNIFI study, demonstrating the efficacy and safety of ustekinumab through two years of treatment in adults with moderately to severely active ulcerative colitis (UC). These data are being presented today as a late-breaking data presentation (LB01) at the 27th UEGW congress.1 These data include 399 participants who were in clinical response eight weeks after receiving a single intravenous (IV) induction dose of ustekinumab and who were then randomised to receive ustekinumab subcutaneous (SC) 90 mg injections every 12 weeks (q12w), ustekinumab SC 90 mg injections every 8 weeks (q8w), or placebo, and who were treated in the long-term extension.1 Results showed that the majority of patients were able to sustain remission through to week 92 as assessed by symptomatic remission. The percentage of patients receiving ustekinumab SC who were in symptomatic remi

H.I.G. Capital Acquires an Office Complex in Lyon21.10.2019 11:10:00 CESTPress release

H.I.G. Capital, LLC ("H.I.G."), a leading global private equity investment firm with over $34 billion of equity capital under management, announced today that one of its affiliates has recently completed the acquisition of an office complex totaling approximately 29,000 sqm in Lyon, France’s second economic centre. The buildings are expected to be delivered in March 2021 and have already been 70% pre-let to an A rated French corporate tenant on a long-term basis. Terms were not disclosed. H.I.G. continues to add to its sizeable holdings of real estate assets across Europe, consisting of both equity as well as debt investments, with a particular focus on its target market of value-added small and midcap opportunities. Riccardo Dallolio, Managing Director and Head of H.I.G. Realty Partners Europe, commented: “Our focus in France is on high delivering quality assets with strong tenants that have the potential of becoming highly liquid institutional product as the result of the envisaged v

Rubicon Project Acquires RTK.io, A Leader in Open Source Header Bidding Solutions21.10.2019 10:00:00 CESTPress release

Rubicon Project (NYSE:RUBI), the global exchange for advertising, today announced the acquisition of RTK.io, a leading provider of tools and services that bring simplicity and control to header bidding for publishers. RTK’s solution is built on Prebid, the same open source framework as Demand Manager, the header bidding solution Rubicon Project launched in May 2019. RTK’s technology and team enable Rubicon Project to extend its Demand Manager product portfolio and client base. In the coming months, the company plans to integrate the two solutions to address the growing needs of publishers globally. Rubicon Project acquired RTK in an all-cash transaction for $11 million. “RTK shares our commitment to open source and our passion for serving publishers with powerful tools and incredible client service,” said Michael Barrett, President and CEO of Rubicon Project. “The company has a strong group of header bidding experts and Prebid developers that adds depth to our already great team. Toget

Alibaba Kicks Off 2019 11.11 Global Shopping Festival21.10.2019 07:31:00 CESTPress release

Alibaba Group Holding Limited (NYSE: BABA) today kicked off its 2019 11.11 Global Shopping Festival, taking the annual celebration into its second decade with a focus on “new consumption,” “new business” and actively contributing to a greener society. “Our goal is to stimulate consumption demand and support lifestyle upgrade in China through new brands and products. We will enable merchants in China and around the world to grow their businesses through data-driven product innovation and consumer insights, as well as leverage our recommendation technology and content-driven user engagement to delight consumers in urban coastal cities and less-developed areas of China,” said Fan Jiang, president of Taobao and Tmall. “Given its scale, minimizing environmental impact is essential and our technology will ensure it is a green 11.11 Global Shopping Festival.” A star-studded gala in Shanghai will count down to the world’s busiest 24 hours of shopping on the evening of November 10th. New Consum

Ebury Makes Landmark Acquisition21.10.2019 06:00:00 CESTPress release

Ebury, one of Europe’s largest fintech companies, is pleased to announce its first acquisition: Frontierpay, an international payroll payments provider with offices in the UK and Singapore. Ebury’s strategy Fast-growing Ebury, has acquired the payroll payments business as part of its expanded technology investment programme. The acquisition forms part of Ebury’s broader strategy to invest in technologies that will help accelerate the automation of international payment processes, specifically targeting those within finance and treasury functions of mid-market corporates. In addition to payments Ebury is investing in technologies that improve the global trade process for SMEs including FX and currency hedging, international cash management and trade finance. It has announced major banking partnerships announced this year with SACE Simest and Unicaja Banco. Frontierpay acquisition Frontierpay, which was founded in 2009, delivers cost effective and reliable payroll payments across 180 cou

AROMA BIT Secures 350mn JPY in Series A Funding from Japan Tobacco and East Ventures21.10.2019 06:00:00 CESTPress release

Aroma Bit, Inc. (Representative Director & CEO: Shunichiro Kuroki, headquarters: Chuo-ku, Tokyo, hereinafter "Aroma Bit"), a company which plans and develops compact odor imaging sensors and innovative services using these sensors, has undertaken an third-party allocation of new shares, up to 350 million yen in total, with Japan Tobacco Inc. (President & CEO: Masamichi Terabatake, headquarters: Minato-ku, Tokyo, hereinafter "JT") and existing shareholder East Ventures, in order to acquire the growth funds needed for future equipment development, business development, etc. Aroma Bit, Inc.: http://www.aromabit.com Purpose of the capital increase: Miniaturization and functionality enhancements for the purpose of expanding the digital olfactory market The compact odor imaging sensor developed by Aroma Bit is a unique odor imaging sensor which, unlike conventional gas sensors that can only detect specific substances, is able to generate a visualization pattern from a variety of odor inputs,